Kiniksa Pharmaceuticals International (KNSA) Cash from Investing Activities (2017 - 2026)

Kiniksa Pharmaceuticals International (KNSA) has reported Cash from Investing Activities for 10 consecutive years, with -$73.6 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Cash from Investing Activities fell 1794.93% year-over-year to -$73.6 million; the trailing twelve-month figure through Jun 2026 stood at -$239.1 million (down 6889.69% YoY), and the FY2025 full-year result was -$189.0 million, down 601.68% from the prior year.
• Cash from Investing Activities declined to -$73.6 million in Q2 2026 per KNSA's latest filing, from -$31.9 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $65.3 million in Q4 2024 and bottomed at -$73.6 million in Q2 2026.
• Historically, Cash from Investing Activities has averaged -$16.4 million across 5 years, with a median of -$18.8 million in 2022.
• The sharpest annual moves came in 2024 and 2026: Cash from Investing Activities surged 538.38% in 2024, then sank 1794.93% in 2026.
• Over 5 years, Cash from Investing Activities stood at -$42.7 million in 2022, then soared by 65.09% to -$14.9 million in 2023, then soared by 538.38% to $65.3 million in 2024, then plunged by 208.46% to -$70.8 million in 2025, then fell by 3.91% to -$73.6 million in 2026.
• According to Business Quant data, Cash from Investing Activities over the past three periods registered -$73.6 million, -$31.9 million, and -$70.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.